SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): August 1, 2012
BioTime, Inc.
(Exact name of registrant as specified in its charter)
California | 1-12830 | 94-3127919 |
(State or other jurisdiction
| (Commission File Number)
| (IRS Employer Identification No.) |
1301 Harbor Bay Parkway
Alameda, California 94502
(Address of principal executive offices)
(510) 521-3390
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
⃞ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
⃞ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
⃞ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
⃞ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Statements made in this Report that are not historical facts may constitute forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those discussed. Such risks and uncertainties include but are not limited to those discussed in this report and in BioTime's other reports filed with the Securities and Exchange Commission. Words such as “expects,” “may,” “will,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions identify forward-looking statements.
Section 8 - Other Events
Item 8.01 - Other Events.
On August 1, 2012, we issued a press release announcing that our subsidiary Cell Cure Neurosciences Ltd. (“Cell Cure”) has been awarded a grant for 2012 in the amount of 5.04 million Shekels, or approximately $1.33 million, from Israel’s Office of the Chief Scientist (“OCS”) to help finance the development of OpRegen®, a cell-based therapeutic product in development by Cell Cure for the treatment of age-related macular degeneration. Age-related macular degeneration is a severe form of acute vision loss, and the leading cause of blindness in an aging population.
The OCS has previously provided grants to Cell Cure. Cell Cure will pay a 3.5% royalty to the OCS on revenues from OpRegen® until total royalties paid equal 100% of the amount of the grants plus interest at a LIBOR rate.
A copy of the press release has been filed as an exhibit to this report.
Section 9 - Financial Statements and Exhibits
Item 9.01 - Financial Statements and Exhibits.
Exhibit Number | Description |
| 99.1 | Press release dated August 1, 2012 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BIOTIME, INC. | ||||
Date: | August 1, 2012 | By: | /s/ Michael D. West | |
| Chief Executive Officer | |||
Exhibit Number | Description |
99.1 | Press release dated August 1, 2012 |
3